Operating Segments

9 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Operating Segments

14. Operating Segments

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. The Company is organized into two segments as follows: (1) the Medical Device unit, which is comprised of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neuro-vascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, as follows (in thousands):

	Three months ended						Nine months ended
	June 30,						June 30,
	2013			2012			2013			2012
Revenue:
Medical Device	$	10,591		$	10,269		$	30,857		$	27,889
In Vitro Diagnostics		3,698			3,690			10,978			10,196
Total revenue	$	14,289		$	13,959		$	41,835		$	38,085
Operating income (loss):
Medical Device	$	5,223		$	5,173		$	15,848		$	13,226
In Vitro Diagnostics		915			1,070			2,933			3,246
Total segment operating income		6,138			6,243			18,781			16,472
Corporate		(1,900	)		(1,450	)		(5,537	)		(4,768	)
Total operating income from continuing operations	$	4,238		$	4,793		$	13,244		$	11,704
Depreciation and amortization:
Medical Device	$	319		$	355		$	947		$	1,073
In Vitro Diagnostics		216			193			649			582
Corporate		193			186			578			559
Total depreciation and amortization	$	728		$	734		$	2,174		$	2,214

The Corporate category includes expenses for administrative corporate functions, such as executive, corporate accounting, legal, human resources and Board of Directors related, that have not been fully allocated to the Medical Device and In Vitro Diagnostics segments. Corporate also includes expenses, such as litigation, which are not specific to a segment and thus not allocated to the segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.